Details of the Drug

General Information of Drug (ID: DMDRQZU)

Drug Name
Ethanol
Synonyms
Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA
Indication
Disease Entry ICD 11 Status REF
Chronic pain MG30 Approved [1], [2], [3]
Cystitis GC00 Approved [1], [2], [3]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 46.07
Topological Polar Surface Area (xlogp) -0.1
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Absorption
The drug is rapidly absorbed [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [6]
Elimination
2.5% of drug is excreted from urine in the unchanged form [5]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2170.63257 micromolar/kg/day [7]
Chemical Identifiers
Formula
C2H6O
IUPAC Name
ethanol
Canonical SMILES
CCO
InChI
InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3
InChIKey
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
702
ChEBI ID
CHEBI:16236
CAS Number
64-17-5
DrugBank ID
DB00898
TTD ID
D00AMQ
VARIDT ID
DR00377
INTEDE ID
DR0655

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Antagonist [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [9]
Aldo-keto reductase 1A1 (AKR1A1) DED2FW3 AK1A1_HUMAN Substrate [12]
Alcohol dehydrogenase class-I alpha (ADH1A) DEE5M8O ADH1A_HUMAN Substrate [13]
Alcohol dehydrogenase class-V (ADH6) DE017IC ADH6_HUMAN Substrate [12]
Gastric alcohol dehydrogenase (ADH7) DEZMAHX ADH7_HUMAN Substrate [12]
Alcohol dehydrogenase class-III (ADH5) DEIOH6A ADHX_HUMAN Substrate [12]
Alcohol dehydrogenase class-I beta (ADH1B) DEEN9RD ADH1B_HUMAN Substrate [13]
Alcohol dehydrogenase class-II (ADH4) DEOCWU3 ADH4_HUMAN Substrate [14]
Alcohol dehydrogenase class-I gamma (ADH1C) DEM1HNL ADH1G_HUMAN Substrate [13]
Alcohol dehydrogenase (ADH) DEG8NJD A0A2I1XAT4_NEISI Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ethanol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [63]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Ethanol and Oliceridine. Acute pain [MG31] [64]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Ethanol and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [65]
Metronidazole DMTIVEN Major Decreased metabolism of Ethanol caused by Metronidazole mediated inhibition of non-CYP450 enzyme. Amoebiasis [1A36] [66]
Cefamandole DMNEXZF Moderate Decreased metabolism of Ethanol caused by Cefamandole mediated inhibition of non-CYP450 enzyme. Anaerobic bacterial infection [1A00-1A09] [67]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [68]
Chlormezanone DMTWUXR Moderate Additive CNS depression effects by the combination of Ethanol and Chlormezanone. Anxiety disorder [6B00-6B0Z] [65]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Ethanol and Desipramine. Attention deficit hyperactivity disorder [6A05] [69]
Cefotetan DM07TX3 Moderate Decreased metabolism of Ethanol caused by Cefotetan mediated inhibition of non-CYP450 enzyme. Bacterial infection [1A00-1C4Z] [67]
Tindamax DM3OWT4 Moderate Decreased metabolism of Ethanol caused by Tindamax mediated inhibition of non-CYP450 enzyme. Bacterial infection [1A00-1C4Z] [66]
Cefoperazone DM53PV8 Moderate Decreased metabolism of Ethanol caused by Cefoperazone mediated inhibition of non-CYP450 enzyme. Bacterial infection [1A00-1C4Z] [67]
Cariprazine DMJYDVK Moderate Additive CNS depression effects by the combination of Ethanol and Cariprazine. Bipolar disorder [6A60] [65]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Ethanol and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [70]
Diphenoxylate DMO5SZX Moderate Additive CNS depression effects by the combination of Ethanol and Diphenoxylate. Bowel habit change [ME05] [65]
Nifurtimox DMSQLZJ Major Decreased metabolism of Ethanol caused by Nifurtimox mediated inhibition of non-CYP450 enzyme. Chagas disease [1F53] [71]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Ethanol and Dihydrocodeine. Chronic pain [MG30] [72]
Levetiracetam DMTGDN8 Moderate Additive CNS depression effects by the combination of Ethanol and Levetiracetam. Chronic pain [MG30] [65]
Levomilnacipran DMV26S8 Moderate Additive CNS depression effects by the combination of Ethanol and Levomilnacipran. Chronic pain [MG30] [65]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Ethanol and Anisindione. Coagulation defect [3B10] [73]
Azelastine DMXTMBJ Moderate Additive CNS depression effects by the combination of Ethanol and Azelastine. Conjunctiva disorder [9A60] [65]
Levonorgestrel DM1DP7T Minor Decreased metabolism of Ethanol caused by Levonorgestrel. Contraceptive management [QA21] [74]
Norgestimate DMYP4XC Minor Decreased metabolism of Ethanol caused by Norgestimate. Contraceptive management [QA21] [75]
Methoxyflurane DML0RAE Moderate Additive CNS depression effects by the combination of Ethanol and Methoxyflurane. Corneal disease [9A76-9A78] [65]
Ketamine DMT5HA4 Moderate Additive CNS depression effects by the combination of Ethanol and Ketamine. Corneal disease [9A76-9A78] [63]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Ethanol and Remifentanil. Corneal disease [9A76-9A78] [64]
Chlophedianol DMXGJEI Moderate Additive CNS depression effects by the combination of Ethanol and Chlophedianol. Cough [MD12] [65]
Sertraline DM0FB1J Moderate Additive CNS depression effects by the combination of Ethanol and Sertraline. Depression [6A70-6A7Z] [65]
Cyclobenzaprine DM1YBRM Moderate Additive CNS depression effects by the combination of Ethanol and Cyclobenzaprine. Depression [6A70-6A7Z] [65]
Vilazodone DM4LECQ Moderate Additive CNS depression effects by the combination of Ethanol and Vilazodone. Depression [6A70-6A7Z] [65]
Nefazodone DM4ZS8M Moderate Additive CNS depression effects by the combination of Ethanol and Nefazodone. Depression [6A70-6A7Z] [65]
Selegiline DM6034S Moderate Additive CNS depression effects by the combination of Ethanol and Selegiline. Depression [6A70-6A7Z] [65]
Vortioxetine DM6F1PU Moderate Additive CNS depression effects by the combination of Ethanol and Vortioxetine. Depression [6A70-6A7Z] [65]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Ethanol and Isocarboxazid. Depression [6A70-6A7Z] [65]
Escitalopram DMFK9HG Moderate Additive CNS depression effects by the combination of Ethanol and Escitalopram. Depression [6A70-6A7Z] [65]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Ethanol and Desvenlafaxine. Depression [6A70-6A7Z] [65]
OPC-34712 DMHG57U Moderate Additive CNS depression effects by the combination of Ethanol and OPC-34712. Depression [6A70-6A7Z] [65]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Ethanol and Doxepin. Depression [6A70-6A7Z] [69]
Maprotiline DMPWB7T Moderate Additive CNS depression effects by the combination of Ethanol and Maprotiline. Depression [6A70-6A7Z] [65]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Ethanol and Esketamine. Depression [6A70-6A7Z] [65]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Ethanol and Mepenzolate. Digestive system disease [DE2Z] [76]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Ethanol and Oxybutynine. Discovery agent [N.A.] [76]
Heroin diacetylmorphine DMDBWHY Moderate Additive CNS depression effects by the combination of Ethanol and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [72]
Tetrabenazine DMYWQ0O Moderate Additive CNS depression effects by the combination of Ethanol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [65]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Ethanol and Deutetrabenazine. Dystonic disorder [8A02] [65]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Ethanol and Ingrezza. Dystonic disorder [8A02] [65]
Fomepizole DM6VOWQ Major Decreased metabolism of Ethanol caused by Fomepizole mediated inhibition of non-CYP450 enzyme. Eexposure to noxious substances harmful effect [NE61] [77]
Oestradiol valerate and dienogest DMZK0FQ Minor Decreased metabolism of Ethanol caused by Oestradiol valerate and dienogest. Endometriosis [GA10] [75]
Zonisamide DM0DTF7 Moderate Additive CNS depression effects by the combination of Ethanol and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [65]
Felbamate DM1V5ZS Moderate Additive CNS depression effects by the combination of Ethanol and Felbamate. Epilepsy/seizure [8A61-8A6Z] [65]
Methsuximide DM6L5VO Moderate Additive CNS depression effects by the combination of Ethanol and Methsuximide. Epilepsy/seizure [8A61-8A6Z] [65]
Gabapentin DM6T924 Moderate Additive CNS depression effects by the combination of Ethanol and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [65]
Cenobamate DMGOVHA Moderate Additive CNS depression effects by the combination of Ethanol and Cenobamate. Epilepsy/seizure [8A61-8A6Z] [65]
Tiagabine DMKSQG0 Moderate Additive CNS depression effects by the combination of Ethanol and Tiagabine. Epilepsy/seizure [8A61-8A6Z] [65]
Fosphenytoin DMOX3LB Moderate Additive CNS depression effects by the combination of Ethanol and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [63]
Brivaracetam DMSEPK8 Moderate Additive CNS depression effects by the combination of Ethanol and Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [65]
Clonazepam DMTO13J Moderate Additive CNS depression effects by the combination of Ethanol and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [78]
Lacosamide DMVM6QR Moderate Additive CNS depression effects by the combination of Ethanol and Lacosamide. Epilepsy/seizure [8A61-8A6Z] [65]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Ethanol and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [79]
Vigabatrin DMYT0OG Moderate Additive CNS depression effects by the combination of Ethanol and Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [65]
Eslicarbazepine DMZREFQ Moderate Additive CNS depression effects by the combination of Ethanol and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [65]
Cannabidiol DM0659E Moderate Additive CNS depression effects by the combination of Ethanol and Cannabidiol. Epileptic encephalopathy [8A62] [65]
Diphenhydramine DMKQTBA Moderate Additive CNS depression effects by the combination of Ethanol and Diphenhydramine. Episodic vestibular syndrome [AB31] [76]
Dantrolene DM1D8XY Moderate Additive CNS depression effects by the combination of Ethanol and Dantrolene. Fever [MG26] [65]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Ethanol and Tolterodine. Functional bladder disorder [GC50] [76]
Ketoconazole DMPZI3Q Minor Decreased metabolism of Ethanol caused by Ketoconazole mediated inhibition of non-CYP450 enzyme. Fungal infection [1F29-1F2F] [80]
Abacavir DMMN36E Minor Decreased metabolism of Ethanol caused by Abacavir mediated inhibition of non-CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [81]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Ethanol and Mipomersen. Hyper-lipoproteinaemia [5C80] [82]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Ethanol and Teriflunomide. Hyper-lipoproteinaemia [5C80] [83]
Belladonna DM2RBWK Moderate Additive CNS depression effects by the combination of Ethanol and Belladonna. Infectious gastroenteritis/colitis [1A40] [76]
Suvorexant DM0E6S3 Moderate Additive CNS depression effects by the combination of Ethanol and Suvorexant. Insomnia [7A00-7A0Z] [65]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Ethanol and Amobarbital. Insomnia [7A00-7A0Z] [79]
Ramelteon DM7IW9J Moderate Additive CNS depression effects by the combination of Ethanol and Ramelteon. Insomnia [7A00-7A0Z] [65]
Zaleplon DMGFWSM Moderate Additive CNS depression effects by the combination of Ethanol and Zaleplon. Insomnia [7A00-7A0Z] [65]
Tasimelteon DMLOQ1V Moderate Additive CNS depression effects by the combination of Ethanol and Tasimelteon. Insomnia [7A00-7A0Z] [65]
Paraldehyde DMOC1BX Moderate Additive CNS depression effects by the combination of Ethanol and Paraldehyde. Insomnia [7A00-7A0Z] [65]
ITI-007 DMUQ1DO Moderate Additive CNS depression effects by the combination of Ethanol and ITI-007. Insomnia [7A00-7A0Z] [65]
Quazepam DMY4D87 Moderate Additive CNS depression effects by the combination of Ethanol and Quazepam. Insomnia [7A00-7A0Z] [78]
Estazolam DMZGXUM Moderate Additive CNS depression effects by the combination of Ethanol and Estazolam. Insomnia [7A00-7A0Z] [78]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [84]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Idelalisib. Mature B-cell leukaemia [2A82] [85]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Ethanol caused by Ethinyl estradiol. Menopausal disorder [GA30] [75]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Ethanol and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [65]
Flibanserin DM70DTN Major Additive CNS depression effects by the combination of Ethanol and Flibanserin. Mood disorder [6A60-6E23] [86]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Ethanol and Thalidomide. Multiple myeloma [2A83] [65]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Ethanol and Phenindamine. Nasopharyngitis [CA00] [65]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Ethanol and Cyclizine. Nausea/vomiting [MD90] [76]
Metoclopramide DMFA5MY Moderate Additive CNS depression effects by the combination of Ethanol and Metoclopramide. Nausea/vomiting [MD90] [65]
E-2007 DMJDYNQ Moderate Additive CNS depression effects by the combination of Ethanol and E-2007. Neuropathy [8C0Z] [65]
Phendimetrazine DM6TS1N Moderate Additive CNS depression effects by the combination of Ethanol and Phendimetrazine. Obesity [5B80-5B81] [87]
Amfepramone DM9YSNQ Moderate Additive CNS depression effects by the combination of Ethanol and Amfepramone. Obesity [5B80-5B81] [87]
Sibutramine DMFJTDI Moderate Additive CNS depression effects by the combination of Ethanol and Sibutramine. Obesity [5B80-5B81] [87]
Dexfenfluramine DMJ7YDS Moderate Additive CNS depression effects by the combination of Ethanol and Dexfenfluramine. Obesity [5B80-5B81] [87]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Ethanol and Levomethadyl Acetate. Opioid use disorder [6C43] [86]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Ethanol and Lofexidine. Opioid use disorder [6C43] [65]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Ethanol and Apraclonidine. Optic nerve disorder [9C40] [88]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Ethanol and Oxymorphone. Pain [MG30-MG3Z] [64]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Ethanol and Dezocine. Pain [MG30-MG3Z] [64]
Flavoxate DMKV4NL Moderate Additive CNS depression effects by the combination of Ethanol and Flavoxate. Pain [MG30-MG3Z] [65]
Methamphetamine DMPM4SK Moderate Additive CNS depression effects by the combination of Ethanol and Methamphetamine. Pain [MG30-MG3Z] [89]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Ethanol and Buprenorphine. Pain [MG30-MG3Z] [90]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Ethanol and Hydrocodone. Pain [MG30-MG3Z] [91]
Ziconotide DMSLJP4 Moderate Additive CNS depression effects by the combination of Ethanol and Ziconotide. Pain [MG30-MG3Z] [65]
Safinamide DM0YWJC Moderate Additive CNS depression effects by the combination of Ethanol and Safinamide. Parkinsonism [8A00] [65]
Pergolide DM14MAE Moderate Additive CNS depression effects by the combination of Ethanol and Pergolide. Parkinsonism [8A00] [65]
Opicapone DM1BKA6 Moderate Additive CNS depression effects by the combination of Ethanol and Opicapone. Parkinsonism [8A00] [65]
Rasagiline DM3WKQ4 Moderate Additive CNS depression effects by the combination of Ethanol and Rasagiline. Parkinsonism [8A00] [65]
Levodopa DMN3E57 Moderate Additive CNS depression effects by the combination of Ethanol and Levodopa. Parkinsonism [8A00] [65]
Bromocriptine DMVE3TK Moderate Additive CNS depression effects by the combination of Ethanol and Bromocriptine. Parkinsonism [8A00] [65]
Orphenadrine DMW542E Moderate Additive CNS depression effects by the combination of Ethanol and Orphenadrine. Parkinsonism [8A00] [65]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Ethanol and Methylscopolamine. Peptic ulcer [DA61] [76]
Neupro DMHEAB1 Moderate Additive CNS depression effects by the combination of Ethanol and Neupro. Restless legs syndrome [7A80] [65]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Ethanol and Leflunomide. Rheumatoid arthritis [FA20] [83]
Aripiprazole DM3NUMH Moderate Additive CNS depression effects by the combination of Ethanol and Aripiprazole. Schizophrenia [6A20] [65]
Iloperidone DM6AUFY Moderate Additive CNS depression effects by the combination of Ethanol and Iloperidone. Schizophrenia [6A20] [65]
Paliperidone DM7NPJS Moderate Additive CNS depression effects by the combination of Ethanol and Paliperidone. Schizophrenia [6A20] [65]
Molindone DMAH70G Moderate Additive CNS depression effects by the combination of Ethanol and Molindone. Schizophrenia [6A20] [65]
Thiothixene DMDINC4 Moderate Additive CNS depression effects by the combination of Ethanol and Thiothixene. Schizophrenia [6A20] [65]
Asenapine DMSQZE2 Moderate Additive CNS depression effects by the combination of Ethanol and Asenapine. Schizophrenia [6A20] [65]
Pimozide DMW83TP Moderate Additive CNS depression effects by the combination of Ethanol and Pimozide. Schizophrenia [6A20] [65]
Avanafil DM75CXN Moderate Additive hypotensive effects by the combination of Ethanol and Avanafil. Sexual dysfunction [HA00-HA01] [92]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [92]
Chlorpheniramine DM5URA2 Moderate Additive CNS depression effects by the combination of Ethanol and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [65]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Ethanol and Acrivastine. Vasomotor/allergic rhinitis [CA08] [65]
⏷ Show the Full List of 123 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2299).
2 Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms. Alcohol Clin Exp Res. 2009 Aug;33(8):1460-8.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 BDDCS applied to over 900 drugs
6 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
9 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
11 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
12 Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
13 Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25.
14 Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
15 Functional profiles of coronal and dentin caries in children. J Oral Microbiol. 2018 Jul 16;10(1):1495976.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
26 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
27 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
28 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
29 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
30 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
31 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
32 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
33 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
34 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
35 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
36 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
37 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
38 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
39 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
40 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
41 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
42 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
43 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
44 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
45 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
46 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
47 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
48 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
49 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
50 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
51 Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
52 Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
53 A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71.
54 Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
55 The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
56 Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
57 13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? Biochem Biophys Res Commun. 2003 Mar 28;303(1):273-8.
58 PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007 Jan;35(1):9-16.
59 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
60 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
61 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
62 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
63 Cerner Multum, Inc. "Australian Product Information.".
64 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
65 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
66 Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985): 292-3. [PMID: 4027157]
67 Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982): 621-2. [PMID: 6214982]
68 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
69 Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
70 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
71 Product Information. Lampit (nifurtimox). Bayer Pharmaceutical Inc, West Haven, CT.
72 Edwards C, Gard PR, Handley SL, Hunter M, Whittington RM "Distalgesic and ethanol-impaired function." Lancet 2 (1982): 384. [PMID: 6124782]
73 Breckenridge A "Clinical implications of enzyme induction." Basic Life Sci 6 (1975): 273-301. [PMID: 239673]
74 Hobbes J, Boutagy J, Shenfield GM "Interactions between ethanol and oral contraceptive steroids." Clin Pharmacol Ther 38 (1985): 371-80. [PMID: 4042520]
75 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
76 Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
77 Product Information. Antizol (fomepizole). Jazz Pharmaceuticals, Palo Alto, CA.
78 Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
79 Gupta RC, Kofoed J "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J 94 (1966): 863-5. [PMID: 5929537]
80 Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
81 Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
82 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
83 Canadian Pharmacists Association.
84 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
85 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
86 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
87 Product Information. Suprenza (phentermine). Akrimax Pharmaceuticals, Cranford, NJ.
88 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
89 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
90 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
91 Product Information. Zohydro ER (HYDROcodone). Zogenix, Inc, San Diego, CA.
92 Cerner Multum, Inc. "UK Summary of Product Characteristics.".